-

11:37:50 AM

NVCN Stock News

NVCN - Neovasc Inc

10/21/21 9:05 AM

Nasdaq : NVCN

Neovasc Reducer™ Featured in Polish Heart Journal

Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced that the Neovasc Reducer™ (“Reducer”) is

RHEA-AI

neutral

09/28/21 9:05 AM

Nasdaq : NVCN

Neovasc REDUCER-I Study Published in EuroIntervention Journal

Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced the publication of an article entitled, “Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective

RHEA-AI

neutral

09/23/21 9:05 AM

Nasdaq : NVCN

conferences

Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference

Neovasc, Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021.

RHEA-AI

neutral

09/16/21 9:05 AM

Nasdaq : NVCN

clinical trialfda approval

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

Neovasc Inc. (“Neovasc” or the “Company”) ( Nasdaq, TSX : NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”)

RHEA-AI

positive

08/30/21 4:05 PM

Nasdaq : NVCN

conferences

Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference

via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September

RHEA-AI

neutral

08/17/21 9:05 AM

Nasdaq : NVCN

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Neovasc Inc. (“Neovasc” or the “Company”) ( Nasdaq, TSX : NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration

RHEA-AI

neutral

08/10/21 4:05 PM

Nasdaq : NVCN

earnings

Neovasc Announces Second Quarter 2021 Financial Results

Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN), today reported financial results for the second quarter ended June 30, 2021. Second Quarter Highlights Generated revenue of approximately $633,000 in

RHEA-AI

neutral

07/27/21 9:05 AM

Nasdaq : NVCN

conferencesearnings

Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021

Neovasc Inc. ( NASDAQ, TSX : NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc’s President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial

RHEA-AI

neutral

07/13/21 9:05 AM

Nasdaq : NVCN

Neovasc Announces New Appointments in Regulatory and Clinical Leadership

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( Nasdaq,

RHEA-AI

positive

06/18/21 9:05 AM

Nasdaq : NVCN

Largest Real-World Registry Supporting Neovasc Reducer™ Safety and Efficacy Outcomes Published in International Journal of Cardiology

Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the

RHEA-AI

neutral

NVCN Data:

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.neovasc.com
CeoFred Colen
Security nameNeovasc Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees71
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
AddressRichmond
Address25138-13562 Maycrest Way
StateBritish Columbia
CityRichmond
ZipV6V 2J7
CountryCanada
Phone16042704344

NVCN Description:

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.